A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples

Leukemia Research

Volumn 35, Issue 7, 2011, Pages 889-898

  Pekova, Sona ^a   Mazal, Oldrich ^a   Cmejla, Radek ^a   Hardekopf, David W ^a   Plachy, Radek ^a   Zejskova, Lenka ^a   Haugvicova, Renata ^a   Jancuskova, Tereza ^a   Karas, Michal ^b   Koza, Vladimir ^b   Smolej, Lukas ^c   Bezdickova, Ludmila ^d   Kozak, Tomas ^d  

^a Chambon Inc   (Czech Republic)

^b Teaching Hospital   (Czech Republic)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

CLL; FASAY; TP53

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; METHYLPREDNISOLONE; PREDNISOLONE; PROTEIN P53; RITUXIMAB; VINCRISTINE;

ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; FOLLOW UP; FRAMESHIFT MUTATION; GENE DELETION; GENE INSERTION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR CLONING; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; TP53 GENE;

ALTERNATIVE SPLICING; BLOTTING, WESTERN; CHROMOSOME DELETION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTAGENESIS, SITE-DIRECTED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79958750215     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.12.016     Document Type: Article

References (21)

1. Lane D.P. Cancer, P53 guardian of the genome. Nature 1992, 358:15-16.
2. Lane D.P., Fischer P.M. Turning the key on p53. Nature 2004, 427:789-790.
3. http://www-p53.iarc.fr/.
4. Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69:1237-1245.
5. Sherr C.J. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006, 6:663-673.
6. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev 2005, 19:2122-2137.
7. Harms K.L., Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol 2005, 25:2014-2030.
8. Nissim-Rafinia M., Kerem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002, 18:123-127.
9. Rohaly G., Chemnitz J., Dehde S., Nunez A.M., Heukeshoven J., Deppert W., et al. A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint. Cell 2005, 122:21-32.
10. Nissim-Rafinia M., Kerem B. The splicing machinery is a genetic modifier of disease severity. Trends Genet 2005, 21:480-483.
11. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 2003, 100:8424-8429.
12. Zenz T., Vollmer D., Trbusek M., Smardova J., Benner A., Soussi T., et al. TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010, [Epub ahead of print].
13. Slovackova J., Grochova D., Navratilova J., Smarda J., Smardova J. Transactivation by temperature-dependent p53 mutants in yeast and human cells. Cell Cycle 2010, 9:11. [Epub ahead of print].
14. Malcikova J., Smardova J., Rocnova L., Tichy B., Kuglik P., Vranova V., et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood 2009, 114:5307-5314.
15. Smardova J. FASAY: a simple functional assay in yeast for identification of p53 mutations in tumors. Neoplasma 1999, 46:80-88.
16. Pekova S., Cmejla R., Smolej L., Kozak T., Spacek M., Prucha M. Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. Leuk Res 2008, 32:395-400.
17. Pekova S., Bezdickova L., Smolej L., Kozak T., Hochova I., Zak P., et al. Quantitation of minimal residual disease in patients with chronic lymphocytic leukemia using locked nucleic acid-modified, fluorescently labeled hybridization probes and real-time PCR technology. Mol Diagn Ther 2007, 11:325-335.
18. Sambrok J, Fritsch EF, Maniatis I. Molecular cloning: a laboratory manual; 1989. ISBN-10:0879693096.
19. Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990, 9:811-818.
20. Reisman D., Loging W.T. Transcriptional regulation of the p53 tumor suppressor gene. Semin Cancer Biol 1998, 8:317-324.
21. Chiorazzi N. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007, 20:399-413.